This novel, competitive immunoassay simuftaneouslydetects seven drugs of abuse in urine. A urine sample is placed in contact with lyophilized reagents, the reaction mixture is allowed to come to equilibrium (10 mm), and then the whole mixture is applied to a solid phase that contains various Immobilized antibodies In discrete drugclass-specific zones. After a washing step, the operator visually examines each zone for the presence of a red bar. (1) (2) (3) (4) (5) . The measurement of the bound ligandconjugate fraction results in a high signal in the absence of analyte, such that the signal decreases with increasing analyte concentration. The assay can be more accurate if the free ligand-conjugate fraction is measured when the free fraction is a small fraction of the total ligand conjugate, such that the observed assay signal increases with increasing analyte concentration (5).
Classically, competitive immunoassays use ligand conjugates and antibodies in proportions that result in partial binding of the ligand conjugates in the absence of analyte (1) (2) (3) (4) (5) . The measurement of the bound ligandconjugate fraction results in a high signal in the absence of analyte, such that the signal decreases with increasing analyte concentration. The assay can be more accurate if the free ligand-conjugate fraction is measured when the free fraction is a small fraction of the total ligand conjugate, such that the observed assay signal increases with increasing analyte concentration (5).
Here we describe a novel immunoassay based on the use of Ascendtm Multixnmunoassaytm technology (U.S. Patents 5028535 and 5089391) for simultaneous detection of multiple analytes in a sample. This technology is used in the Triagetm panel (Biosite Diagnostics, Inc., San Diego, CA) for detection of seven classes of drugs of abuse. The Triage panel contains all of the reagents necessary to perform the assay. The assay procedure takes -10 mm and is performed in three simple steps. The technology meets the growing need to provide rapid, accurate results on-site in a noninstrumented format. The method incorporates individual preset threshold concentrations for each drug. The threshold concentration for each drug is predetermined in terms of the amount of high-affinity monoclonal antibody required to completely bind the drug conjugate and the drug in the sample at concentrations up to the threshold concentration of drug. The assay response is proportional to the concentration of the unbound drug conjugate so that no signal is observed at drug concentrations less than the threshold concentration. At drug concentrations exceeding the threshold concentration, a color response is achieved. The rate of increase of the color response above the threshold concentration is a function of the relative affinities of the antibody for each of the drug metabolites and the drug conjugate and is related to the absolute affinity of the antibody for the drug conjugate. Thus, a digital response can be achieved at the threshold concentration by using antibodies having the proper affinity. where F is the ratio of free to bound ligand, L is the total concentration of ligand, R is the total concentration of ligand-receptor binding sites, and K is the equilibrium Total Ligand Concentration (R units) Fig. 1 . Effect of the equilibrium binding constant on the assay responsefunction binding constant. As the value of R increases relative to that of 1/K (that is, the receptor concentration is substantially greater than the dissociation constant), the functional form of a plot of free ligand as a function of total ligand concentration approaches that of a step function (Figure 1) . Furthermore, the curvature at the step is related to the relationship between the equilibrium binding constant, K, and the total ligand-receptor binding site concentration, R. The free ligand fraction is directly related to the free ligand-conjugate fraction, which determines the assay response function. As R increases relative to 1/K, Figure 1 shows that a more dramatic step increase in the free ligand or free ligand-conjugate fraction occurs. To achieve a dramatic stepwise increase in the free ligand or free ligand.-conjugate fraction, one selects ligand receptors of increasing equilibrium constant, K. The relationship between the free ligand or the free ligand-conjugate fraction and the ratio of free to bound ligand, F, is given as
Furthermore, when R is sufficiently larger than 1/K, the concentration position of the step is a function of the relative value of R, the receptor binding-site concentration. As illustrated in Figure 2 , increasing the value of R increases the concentration corresponding to the position of the step.
For these relationships to apply to ligand-receptor assays, the ligand conjugates and ligand receptors must be provided in such amounts that, when at equilibrium in a mixture with Figure 2 , the threshold concentration can be selected by appropriate choice of the concentration of ligand receptor. Thus, no response is observed until the ligand concentration exceeds its threshold. Figure 1 shows that the rate of increase of the free ligand and the free fraction of ligand conjugate as a function of total ligand concentration are determined by the equilibrium binding constant and its relationship to the threshold concentration. A suitable equilibrium binding constant is sufficient to reduce the response from the free ligand conjugate to less than the response noise of the assay.
When the equilibrium binding constants for the binding of receptor to ligand and ligand conjugate are not substantially equivalent, the slope of the responsefunction above the threshold concentration is determined by the relative magnitudes of the respective equilibrium binding constants. When these binding constants are substantially equivalent, the response functions depicted in Figure 1 describe the assay response. When the binding constants are not substantially equivalent, the response function varies as depicted in Figure 3 . When the magnitude of the equilibrium binding constant of the ligand receptor for the ligand conjugate, K5, is greater than that for the ligand, K, the slope of the response function is decreased because more ligand is required to compete effectively with a given concentration of ligand conjugate. Conversely, when the magnitude of the equilibrium binding constant of the ligand receptor for binding to ligand conjugate is less than that for binding to ligand, the slope of the response function is correspondingly increased because less ligand is necessary to corn- The reagents of the Triage panel consist of three lyophilized beads contained in the reaction well of the device. These beads contain the buffer, the antibodies, and the colloidal gold-drug conjugates. The buffer bead maintains the pH of the reaction mixture between 7.5 and 8.5. The antibody bead contains the set of monoclenal antibodies specific for the target drug metabolites in urine. The colloidal gold conjugate bead contains conjugates of drug-labeled bovine serum albumin adsorbed to colloidal gold by a modification of the procedure of Geoghegan and Ackerman (6) . The bottom of the reaction well of the device contains a powdered mixture of citric acid and bicarbonate, separated from the three lyophilized beads by a porous plastic disc. The powder and disc create a controlled effervescence upon addition of the urine sample. The effervescence actively mixes the reagents of the reaction mixture during the incubation period.
The antibodies for the detection of the unbound colloidal gold-drug conjugates are immobilized by passive adsorption to a nylon membrane. The membrane is contained in a plastic device that is designed to maintain contact of the reaction mixture with the entire surface of the membrane before the flow of fluid through the membrane.
The wash solution contains potassium borate (100 mmoIJL), sodium chloride (150 mmol/L), a detergent, and sodium azide (0.2 g/L), pH 10.
Methods
The assay protocol for the Triage panel was performed as indicated in the product insert: we added a urine sample (0.14 mL) to the reaction cup of the device, using the pipet supplied in the kit, and incubated the reaction mixture at room temperature for 10 mm. Using the pipet, we qualitatively transferred the reaction mixture to the detection area and allowed the solution to drain through the membrane. We then added three drops of wash solution and let this completely drain through the membrane. The appearance of a red bar in the detection zone of a drug was read as a positive result for the respective drug; a negative result was read when no color was observed. A positive result for the Control-Positive zone and a negative result for the Control-Negative zone verified that the procedure was properly performed. The appearance of either a negative Control-Positive result or a positive Control-Negative result invalidated the determination.
For confirmation, we performed gas chromatography/ mass spectrometry (GC/MS) with a Hewlett-Packard (Palo Alto, CA) Model 5890CC and a 5970 series MS detector.' The instrument was operated in the splitlees injection mode and the selective ion monitoring mode. We used an HP-i (Hewlett-Packard) chromatographic 'Nonstandard abbreviations: GC/MS, gas chromatography/ massspectrometry; PCP,phencydidine; and THC, tetrahydrocan- PCP was not derivitized but was extracted as stated above.
Results

Antibody BindingReactions
The Triage panel for drugs of abuse is a practical implementation of Ascend Multimmunoassay technology. Upon addition of the urine sample to the reaction cup within the device, the lyophilized reagents are dissolved and mixed by effervescence.A 10-mm incubation allows the immunological reactions to come to equilibrium. In the absence of drug or in the presence of drug up to the threshold concentration, the quantity of antibody in the test is sufficient to bind all of the drug on the colloidal gold conjugates, resulting in bound drug conjugates. The bound drug conjugates cannot in the subsequent step bind to the antibodies immobilized on the membrane, and therefore no colored bar is observed. When drug is present in the sample at or above the threshold concentration, the drug and the drug conjugate compete for the limited number of antibody binding sites, with the result that, at equilibrium, a portion of the drug conjugate remains free. The free drug conjugates then bind to their respective antibodies immobilized in the detection zones on the membrane and one or more colored bars are then observed. Twenty replicate assays were performedof urine samples supplementedwith selected drugconcentrations zoylecgonine are shown in Figure 5 (top, middle, and bottom, respectively). The slope for the results of the cocaine metabolite analysis is more shallow than for the PCP and THC metabolite analyses. This difference in slope reflects the substantially greater affinity of the cocaine metabolite antibody for the cocaine metabolite conjugate relative to its affinity for the cocaine metabolite. For assays in which lower threshold concentrations are desired, the position of the threshold curve can be shifted to detect samples containing lower drug concentrations. These results show that the onset of visible signals occurs in a narrow concentration range.
Correlation with GC/MS and EMIT Assays
The clinical specimens used for the correlation studies Triage panel are 25 j.tg/L for PCP, 300 zgIL for benzodiazepine metabolites, 300 jig/L for cocaine metabolite, 1000 zg/L for amphetamine, 1000 agIL for methamphetamine, 100 gIL for THC metabolite, 300 pg/L for opiates, and 300 ug/L for barbiturates. Table 1 compares the clinical sensitivity and specificity of the Triage panel with GC/MS and EMIT assays. The results of the three assays correlated very well.
Antibody Specificity
The monoclonal antibodies used in the Triage panel for drugs of abuse were selected to be specific for the urinary metabolites of the drugs of abuse. This specificity for metabolites is particularly important for the benzodiazepines, opiates, and cannabinoids because these classes of drugs are metabolized and excreted primarily as glucuronide conjugates (7-11). Therefore, antibodies that are more specific for the parent drug may not accurately measure the substance(s)present in urine. Table 2 shows the reactivity of the antibodies for several parent drugs and drug metabolites of the benzodiazepines, opiates, and cannabinoids. The antibody specificity for the primary metabolites is high. Assays of the glucuronides of the benzodiazepines listed in Table 2 were judged positive at the threshold concentration of 300 zgfL, whereas assays of the parent compounds were generally judged positive at concentrations higher than the threshold concentration. The reactivity of the antibodies for the class of barbiturates is shown in Table 3 . At a threshold concentration of 300 g/L, broad specificity was demonstrated for the barbiturates listed, except for phenobarbital, which was detected at 450 ig/L. The reactivity of the antibodies to the amphetamines is also presented in Table 3 . The threshold concentration was set at 1000 pg/L each for d-amphetamine and d-methamphetainine; in this detection zone, the 1-isomers of amphetamine and methamphetamine tested negative up to 35000 and 10000 &g/L, respectively. Thus, the antibodies preferentially recognize the d-isomers of the amphetamines, which is desirable because the i-isomer of methamphetamine is found in some medications (12). Most confirmation methods currently used do not detect the different stereoisomers and thus can give false-positive results.
Several common cross-reactants in the amphetamine assays are listed in Table 4 These specificity results indicate that the monoclonal antibodies in the Triage panel detect the major metabolites of the drugs of abuse found in urine. The monoclonal antibodies used in the assays for classes of drugs such as barbiturates were selected for their ability to detect the entire class of compounds.
DIscussion
Competitive immunoassays, including those for drugs of abuse, have been dominated by instrument-based formats. Visually interpreted competitive immunoassays have not been widely adopted because of the difficulty in developing calibration methods for such assays. Before development of the method described in this paper, visually interpreted competitive immunoassays were calibrated in two ways. The first procedure used was to develop assays with a low slope in the dose-response curve, purposefully reducing the sensitivity of the assay so that positive responses would be first observed at the threshold concentration. For example, latex agglutination assays must use this method of calibration, which results in poor discrimination of positive samples from negative samples near the threshold concentration. The secondprocedure for calibrating assays used external calibrators. For example, colorimetric visual assays can also be calibrated by using separate tests of calibrators or reference color charts to compare the assay response of the sample with the response of the calibrator. Because such comparisons are subjective, assay accuracy is generally poor relative to instrument-based assays. Moreover, color comparisons become substantially more complex when assays are performed for several analytes simultaneously.
The Triage assay panel for drugs of abuse is internally calibrated through the application of Ascend Multinimunoassay technology. The ability of this assay technology to discriminate concentrations of drugs around the threshold concentration is not compromised relative to instrument-based systems. The presence of a red bar in the discrete zone specific for a drug or drug class signifies a positive result No additional external color comparisonsare necessary, and the color endpoint is stable for at least 10 mm. Internal procedural controls provide additional information to the operator to ensure that each assay procedure was performed correctly and that the sample did not contain adulteranta that can cause falsepositive or false-negative results. The exclusive use of high-affinity monoclonal antibodies ensures reproducible sensitivity and specificity for each assay, in comparison with instrument-based systems, and lyophilized reagents provide long-term stability at room temperature. The Triage panel for drugs of abuse represents a new generation of competitive immunoassays. The Ascend Multimmunoassay technology allows for assay formats that are simple for the user and gives assay results equivalent to those for assaysperformed on instruments.
